Enter your keywords
HOME
About Us
NEWSLETTER
To search AlzRisk, use the "Keyword" search on the
AlzRisk search page
.
NEWS
All News
Conference Coverage
Series
WEBINARS
All Webinars
Databases
AlzBiomarker
AlzPedia
AlzRisk
Antibodies
Genetics
AlzGene
HEX
Mutations
Protocols
Research Models
Therapeutics
PAPERS
All Papers
Papers of the Week
Milestone
Alzforum Recommends
PROFESSIONAL RESOURCES
Conference Calendar
Grants
Jobs
Member Directory
ABOUT AD
AD Overview
Early-Onset Familial
The HBO Alzheimer's Project
Supported Browsers
MY ALZFORUM
My AlzForum Home
View Library
View Notifications
Set Notifications
Edit Profile
AlzRisk Paper Detail
Risk Factors
Alcohol
B Vitamins
Blood Pressure
Cognitive Activity
Diabetes Mellitus
Dietary Pattern
Head injury
Homocysteine
Hormone Therapy
Inflammatory Biomarkers
Non-Steroidal Anti-Inflammatory Drugs
Nutritional Antioxidants
Obesity
Physical Activity
Statin use
Reference:
Arvanitakis, 2004
Cohort:
Religious Orders Study
Risk Factor:
Diabetes Mellitus
Exposure Detail
"Diabetes mellitus was considered present if the participant was taking a medication to treat diabetes mellitus, reported a history of diagnosis of diabetes mellitus, or both." The authors classified a participant as diabetic if s/he met these criteria at any time during the study.
Ethnicity Detail
Not reported.
According to a
description
of the cohort, approximately 89% of the cohort members were white.
Screening and Diagnosis Detail
Screening Method:
CERAD
Consortium to Establish a Registry for Alzheimer's Disease (Morris 1989)
AD Diagnosis:
NINCDS ADRDA
National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association Criteria (McKhann 1984)
"At baseline, each participant underwent a uniform structured clinical evaluation that followed the procedures recommended by the Consortium to Establish a Registry for Alzheimer’s Disease (16). The evaluation included a medical history, a neurologic examination, neuropsychological performance testing, and a review of a brain scan when available. All prescription and over-the-counter medication names and dosages were recorded after direct inspection of medication containers. A board-certified neuropsychologist (R.S.W.) reviewed the cognitive performance test results. Participants were evaluated in person by a neurologist (Z.A. or D.A.B.) or a geriatrician with expertise in the evaluation of older persons with and without dementia. Based on this evaluation, persons were classified with respect to AD, stroke, and other common conditions with the potential to impact cognitive function. Details of the evaluations have been previously described (15,17). The diagnosis of dementia and AD followed the recommendations of the joint working group of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (18) The diagnosis of clinical stroke was based on review of the medical history, neurologic examination results, and neuroimaging data (brain computed tomography and/or magnetic resonance imaging scans) when available, as previously described (15). Follow-up evaluations were identical in all essential details to the baseline evaluation, and were performed annually by examiners blinded to previously collected data."
Covariates & Analysis Detail
Analysis Type:
Cox proportional hazards regression
AD Covariates:
A
age
E
education
G
gender
SH
stroke history